Our Blog

iSpecimen Marketplace® helps life science researchers in industry, government, and academia streamline the procurement of human biospecimens for their upstream research and work on treatments and diagnostics. The Marketplace also facilitates the sharing of specimens through our global network of biospecimen suppliers-including hospitals, labs, biobanks, and blood centers-by providing human biofluids, tissue, and cells for…

Plastics are ubiquitous in the developed world, and scientists have long known that humans breathe and inadvertently eat microscopic fragments – equivalent, by one account, to a credit card’s worth plastic every week. Now, for the first time, Dutch researchers have proved micro- and nanoplastic particles from the environment end up in the human bloodstream. It’s the latest discovery affirming the importance of human biospecimens in advancing medical progress.

Looks do matter, at least when it comes to immune system performance, suggests a new study.

Some of the best values are hidden in plain sight, like Toyotas, index funds and refurbished electronics. The same is true in the biospecimen world. Let us walk you through it. We’re known by many clients for giving researchers access to millions of banked and clinical remnant samples through our online platform, the iSpecimen Marketplace,…

Why do roughly 1 in 3 COVID-19 patients experience symptoms lasting a month or more? And which newly diagnosed patients will develop so-called “long COVID”? Researchers may be approaching answers with the discovery that reduced levels of certain antibodies in the blood may help predict who will suffer long COVID.

As the pandemic continues to rear its ugly head this winter, we have strengthened our fight against the disease by expanding our supplier network with the addition of a new reference lab in New York to support commercial and government customers focused on COVID-19 research involving the Omicron and Delta variants. The reference lab has…

Lung cancer is a leading cause of cancer death, making up nearly 25% of all cancer deaths (not all of which are smoking-related), but only 5% to 6% of at-risk Americans undergo recommended CT screening, with many concerned about radiation exposure and invasive procedures.

Irritable bowel syndrome (or IBS), characterized by stomach pain, bloating, cramping, constipation and diarrhea, is diagnosed in an estimated 1.3% of U.S. adults. In a country of 330 million, that’s a lot.

We’re seeing encouraging progress in cancer diagnostics with news of positive results from an innovative blood test to detect circulating tumor DNA.